State Street Corp Purchases 116,094 Shares of Acelyrin, Inc. (NASDAQ:SLRN)

State Street Corp raised its position in shares of Acelyrin, Inc. (NASDAQ:SLRN) by 10.0% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,273,096 shares of the company’s stock after buying an additional 116,094 shares during the period. State Street Corp owned about 1.28% of Acelyrin worth $6,276,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Point72 Asset Management L.P. lifted its holdings in Acelyrin by 566.7% in the 3rd quarter. Point72 Asset Management L.P. now owns 250,300 shares of the company’s stock worth $1,234,000 after buying an additional 212,758 shares during the period. HighTower Advisors LLC purchased a new stake in Acelyrin in the third quarter worth $50,000. Verition Fund Management LLC lifted its stake in Acelyrin by 55.1% in the third quarter. Verition Fund Management LLC now owns 110,115 shares of the company’s stock worth $543,000 after acquiring an additional 39,100 shares during the period. Martingale Asset Management L P bought a new stake in Acelyrin in the third quarter valued at $485,000. Finally, Acuta Capital Partners LLC purchased a new position in Acelyrin during the 3rd quarter valued at $1,795,000. Institutional investors own 87.31% of the company’s stock.

Analysts Set New Price Targets

SLRN has been the subject of several research analyst reports. Wells Fargo & Company dropped their target price on shares of Acelyrin from $15.00 to $13.00 and set an “overweight” rating for the company in a research report on Wednesday, December 11th. HC Wainwright restated a “neutral” rating and issued a $8.00 price objective on shares of Acelyrin in a report on Wednesday, December 11th.

Acelyrin Trading Down 2.1 %

SLRN opened at $3.25 on Friday. Acelyrin, Inc. has a 12-month low of $3.06 and a 12-month high of $8.89. The company has a market cap of $326.06 million, a price-to-earnings ratio of -1.32 and a beta of 1.61. The stock has a fifty day simple moving average of $4.73 and a two-hundred day simple moving average of $4.93.

Acelyrin Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.